Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Letizia Porcelli, Gabriella Guida, Anna E. Quatrale, Tiziana Cocco, Letizia Sidella, Immacolata Maida, Rosa M. Iacobazzi, Anna Ferretta, Diana A. Stolfa, Sabino Strippoli, Stefania Guida, Stefania Tommasi, Michele Guida, Amalia Azzariti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target. Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of drug resistance and response were investigated. Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status. Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination was more effective than each drug alone in all cells. Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in metastatic melanoma treatment.

Original languageEnglish
Article number26
JournalJournal of Translational Medicine
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 27 2015

Fingerprint

Aurora Kinase B
Chemotherapy
Melanoma
Drug Therapy
Pharmaceutical Preparations
Cells
Cell Movement
Cell growth
Metabolism
Lactic Acid
Phosphotransferases
Chemical activation
PLX4032
Association reactions
Apoptosis
Therapeutics
Drug Resistance
2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
Cell Cycle
Necrosis

Keywords

  • Barasertib
  • BRAF status
  • Melanoma
  • Nab-paclitaxel
  • Vemurafenib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. / Porcelli, Letizia; Guida, Gabriella; Quatrale, Anna E.; Cocco, Tiziana; Sidella, Letizia; Maida, Immacolata; Iacobazzi, Rosa M.; Ferretta, Anna; Stolfa, Diana A.; Strippoli, Sabino; Guida, Stefania; Tommasi, Stefania; Guida, Michele; Azzariti, Amalia.

In: Journal of Translational Medicine, Vol. 13, No. 1, 26, 27.01.2015.

Research output: Contribution to journalArticle

Porcelli, L, Guida, G, Quatrale, AE, Cocco, T, Sidella, L, Maida, I, Iacobazzi, RM, Ferretta, A, Stolfa, DA, Strippoli, S, Guida, S, Tommasi, S, Guida, M & Azzariti, A 2015, 'Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy', Journal of Translational Medicine, vol. 13, no. 1, 26. https://doi.org/10.1186/s12967-015-0385-4
Porcelli, Letizia ; Guida, Gabriella ; Quatrale, Anna E. ; Cocco, Tiziana ; Sidella, Letizia ; Maida, Immacolata ; Iacobazzi, Rosa M. ; Ferretta, Anna ; Stolfa, Diana A. ; Strippoli, Sabino ; Guida, Stefania ; Tommasi, Stefania ; Guida, Michele ; Azzariti, Amalia. / Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. In: Journal of Translational Medicine. 2015 ; Vol. 13, No. 1.
@article{8279fe7ce6ca4e9a8cd88b787c9f2ed4,
title = "Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy",
abstract = "Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target. Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of drug resistance and response were investigated. Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status. Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination was more effective than each drug alone in all cells. Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in metastatic melanoma treatment.",
keywords = "Barasertib, BRAF status, Melanoma, Nab-paclitaxel, Vemurafenib",
author = "Letizia Porcelli and Gabriella Guida and Quatrale, {Anna E.} and Tiziana Cocco and Letizia Sidella and Immacolata Maida and Iacobazzi, {Rosa M.} and Anna Ferretta and Stolfa, {Diana A.} and Sabino Strippoli and Stefania Guida and Stefania Tommasi and Michele Guida and Amalia Azzariti",
year = "2015",
month = "1",
day = "27",
doi = "10.1186/s12967-015-0385-4",
language = "English",
volume = "13",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

AU - Porcelli, Letizia

AU - Guida, Gabriella

AU - Quatrale, Anna E.

AU - Cocco, Tiziana

AU - Sidella, Letizia

AU - Maida, Immacolata

AU - Iacobazzi, Rosa M.

AU - Ferretta, Anna

AU - Stolfa, Diana A.

AU - Strippoli, Sabino

AU - Guida, Stefania

AU - Tommasi, Stefania

AU - Guida, Michele

AU - Azzariti, Amalia

PY - 2015/1/27

Y1 - 2015/1/27

N2 - Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target. Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of drug resistance and response were investigated. Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status. Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination was more effective than each drug alone in all cells. Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in metastatic melanoma treatment.

AB - Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target. Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of drug resistance and response were investigated. Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status. Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination was more effective than each drug alone in all cells. Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in metastatic melanoma treatment.

KW - Barasertib

KW - BRAF status

KW - Melanoma

KW - Nab-paclitaxel

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84938200163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938200163&partnerID=8YFLogxK

U2 - 10.1186/s12967-015-0385-4

DO - 10.1186/s12967-015-0385-4

M3 - Article

AN - SCOPUS:84938200163

VL - 13

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 26

ER -